OUR MATERIAL
Our materials consist of two nanocomposite polymers used in the development of surgical implants/medical devices. Both polymers are based on unique chemical formulations with functionalised graphene oxide nanoparticles.
Hastalex® is non-biodegradable with applications including heart valves, tendons, pelvic mesh, and dental implants. BioHastalex® is biodegradable in sea water and landfills, clinical applications include a broad range of use across women’s health and tissue engineering products for skin and wound healing.
Both polymers have been tested and found to be biocompatible and non-toxic. Due to the conjugation of graphene nanoparticles into the polymer structure, both polymers harness the unique properties of graphene and are strong, elastic, and antibacterial.
NOVEL PRODUCT DEVELOPMENT
We are developing a range of products addressing the unmet needs in women’s health, supporting women as they navigate different health conditions at different life-stages.
We hope to shape the future of women’s health and break the taboos and stigmas associated with women’s health conditions, by developing therapeutics designed to meet their needs.
MENSTRUAL HEALTH
Menstruation is a normal and healthy part of life for most women, with around half of the female population being of reproductive age and requiring access to female hygiene products.
THE GLOBAL FEMININE HYGIENE PRODUCTS MARKET WAS VALUED AT $38.9 BILLION IN 2020, AND IS PROJECTED TO REACH $68.7 BILLION BY 2030.
OUR OBJECTIVE IS TO DEVELOP A RANGE OF INNOVATIVE PRODUCTS TO IMPROVE MENSTRUAL WELL-BEING.
Conventional panty liners can increase temperature, skin surface moisture and pH of vulval skin thereby changing the microbiome of the vagina. Our unique female hygiene products consists of high-quality material (Biohastalex) which is non-toxic, minimising local sensitivity. It is also ultra-thin and flexible making it comfortable to use, but equally strong to provide good leakage protection.
SUSTAINABILITY IS IMPORTANT TO US
Our range of vaginal cups and discs are reusable and biodegradable, setting it apart from other products on the market. These novel alternatives, provide consumers with options to choose the products that best fit their needs.
PELVIC PAIN & ENDOMETRIOSIS
ENDOMETRIOSIS IMPACTS 1 IN 10 WOMEN, WHICH EQUATES TO 176 MILLION WOMEN WORLDWIDE AND COSTS THE UK
ECONOMY £8.2 BILLION A YEAR IN TREATMENT, LOSS OF WORK AND HEALTH CARE COSTS.
THE CAUSE OF ENDOMETRIOSIS IS UNKNOWN AND THERE IS NO DEFINITIVE CURE WITH MANAGEMENT OPTIONS LARGELY DEPENDENT ON SYMPTOM CONTROL.
OUR OBJECTIVE…
is to develop a vaginal drug delivery system for the management of chronic gynaecological disease. This novel system will provide individualised, targeted treatment for the management of pelvic pain associated with conditions such as endometriosis and chronic bladder pain syndrome.
INCONTINENCE AND PROLAPSE
Pelvic organ prolapse (POP) and incontinence affects women of all ages, however, older women are more prone to POP disorders.
ACCORDING TO THE US FDA REPORTS, THE NUMBER OF WOMEN WHO HAVE POP IS EXPECTED TO INCREASE BY 46%, TO 4.9 MILLION, BY 2050.
The urinary incontinence and pelvic organ prolapse devices and equipment market has been curtailed by rising health issues due to the use of vaginal mesh for the treatment of UI and POP.
Commissioned in 2018, The Cumberlage review was inspired by patient campaigns alleging harm from intervention and medical devices. One such medical treatment is pelvic mesh, a surgical material (medical device) implanted in thousands of women to treat organ prolapse and urinary incontinence. Mesh is now the subject of intense global scrutiny after reports of long- term effects from this material that has, migrated, eroded or caused severe allergic reactions.
OUR OBJECTIVE…
at Liberum Health is to develop a safe alternative to polypropylene mesh as well as innovative products for the management of prolapse. We are in the concept stage of researching a substitute product that would be made using graphene-based nanocomposite material.
MENOPAUSE
The global menopause market size was valued at USD 14.7 BILLION IN 2020 and is expected to expand to reach USD 22.7 BILLION BY 2028. As a result of an ageing population, approximately 1 BILLION WOMEN WILL BE MENOPAUSAL GLOBALLY BY 2025. Many women will spend UP TO 40% OF THEIR LIVES IN THE POSTMENOPAUSAL STAGE.
There are over 30 symptoms attributed to menopause, including vasomotor symptoms such as hot flushes and night sweats. The pandemic and recent large nationwide campaigns, has led to a growing awareness regarding menopause and its impact on day-to-day living.